Early proactive monitoring of DNA-thioguanine in patients with Crohn’s disease predicts thiopurine-induced late leucopenia in NUDT15/TPMT normal metabolizers

Figure 8 Nomogram based on the multivariate analysis results shown in Table 2. For example, a 65-year-old patient with the wild-type nudix hydrolase 15 (NUDT15)*1/*1, having a DNA-thioguanine (DNATG) concentration of 200 fmol/μg DNA, would score 70 for age, 20 for DNATG concentration, and 0 for the NUDT15 genotype, resulting in a total score of 90. Correspondingly, the estimated 1-year, 2-year, and 3-year well-tolerated (no occurrence of late leukopenia) probabilities are approximately 0.6, 0.4, and 0.3, respectively. DNATG: DNA-thioguanine; NUDT15: Nudix hydrolase 15.